SGLT-2抑制剂与DPP-4抑制剂联用二甲双胍治疗2型糖尿病的疗效分析  

Effect Analysis of SGLT-2 Inhibitor and DPP-4 Inhibitor Combined with Metformin in the Treatment of Type 2 Diabetes Mellitus

作　　者：陈倩 陈兴钰 李媛 CHEN Qian;CHEN XingYu;LI Yuan(Department of Pharmacy,the Second People's Hospital of Liangshan Yi Autonomous Prefecture,Liangshan,Sichuan Province,615000 China)

机构地区：[1]凉山彝族自治州第二人民医院药学部,四川凉山615000

出　　处：《糖尿病新世界》2023年第5期73-76,共4页Diabetes New World Magazine

摘　　要：目的研究钠-葡萄糖协同转运蛋白2(sodium-dependent glucose transporters 2,SGLT-2)抑制剂与二肽基肽酶4(dipeptidyl peptidase 4,DPP-4)抑制剂联合二甲双胍治疗2型糖尿病的疗效与安全性。方法选取2019年6月—2020年6月凉山彝族自治州第二人民医院收治的100例2型糖尿病患者进行研究,并运用随机数表法将其分为对照组(n=50)和研究组(n=50)。对照组采用DPP-4抑制剂+二甲双胍治疗,研究组采用SGLT-2抑制剂+DPP-4抑制剂+二甲双胍治疗。对比治疗前后两组血糖指标、体质指数(BMI)变化情况、不良反应发生情况。结果治疗前,两组患者血糖指标、BMI比较,差异无统计学意义(P>0.05)。治疗后,研究组空腹血糖、餐后2 h血糖、糖化血红蛋白水平及BMI低于对照组,差异有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论采用SGLT-2抑制剂+DPP-4抑制剂+二甲双胍进行治疗,可以改善2型糖尿病患者血糖水平,控制患者体质量,总体疗效良好。Objective To investigate the efficacy and safety of sodium-glucose cotransporter 2(SGLT-2)inhibitor and dipeptidyl peptidase 4(DPP-4)inhibitor combined with metformin in the treatment of type 2 diabetes mellitus.Methods 100 patients with type 2 diabetes admitted to the Second People's Hospital of Liangshan Yi Autonomous Prefecture from June 2019 to June 2020 were selected for the study,and were divided into the control group(n=50)and the study group(n=50)by using the random number table method.The control group was treated with DPP-4 inhibitor+metformin,while the study group was treated with SGLT-2 inhibitor+DPP-4 inhibitor+metformin.Compared the changes in blood glucose indicators,body mass index(BMI)before and after treatment,and adverse reactions after treatment between the two groups.Results Before treatment,there was no statistically significant difference between the two groups in blood glucose indicators and BMI(P>0.05).After treatment,the fasting blood glucose,2 hour postprandial blood glucose,glycosylated hemoglobin levels,and BMI in the study group were lower than those in the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Treatment with SGLT-2 inhibitor+DPP-4 inhibitor+metformin can improve the blood glucose level and control the weight of patients with type 2 diabetes,and the overall effect is good.

关 键 词：SGLT-2抑制剂 DPP-4抑制剂 二甲双胍 2型糖尿病 

分 类 号：R4[医药卫生—临床医学]